Fieldview Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Fieldview Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-268	Closed	-$207K	–	673
2026 Q1	$207K	Buy	+268	New	+$205K	0.06%	451
2025 Q4	–	Sell	-365	Closed	-$205K	–	615
2025 Q3	$205K	Buy	+365	New	+$206K	0.03%	374
2025 Q2	–	Sell	-642	Closed	-$407K	–	486
2025 Q1	$407K	Sell	642 -2,892	-82%	-$1.99M	0.06%	302
2024 Q4	$2.52M	Buy	+3,534	New	+$2.97M	0.39%	85

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fieldview Capital Management's REGN Position: Q2 2026 in Review

Fieldview Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 268 shares — an estimated $207K sold.

Fieldview Capital Management first reported a position in REGN in Q4 2024 and held it in 4 quarters. The position peaked at $2.52M in Q4 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Fieldview Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Fieldview Capital Management sold 268 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $207K.
Fieldview Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Fieldview Capital Management's Regeneron Pharmaceuticals position peaked at $2.52M in Q4 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.